期刊
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
卷 54, 期 6, 页码 1021-1030出版社
WALTER DE GRUYTER GMBH
DOI: 10.1515/cclm-2015-0879
关键词
free light chains; harmonisation; monoclonal gammopathy; M-protein; plasma cell dyscrasia; standardisation
资金
- Netherlands Organization for Health Research [NWO-Veni-016.136.101]
- Associazione Italiana per la Ricerca sul Cancro Special Program Molecular Clinical Oncology 5 per mille [9965]
- Fondazione Cariplo [2013-0964]
The serum free light chain (FLC) assay has proven to be an important complementary test in the management of patients with monoclonal gammopathies. The serum FLC assay has value for patients with plasma cell disorders in the context of screening and diagnosis, prognostic stratification, and quantitative monitoring. Nonetheless, serum FLC measurements have analytical limitations which give rise to differences in FLC reporting depending on which FLC assay and analytical platform is used. As the FLC measurements are incorporated in the International Myeloma Working Group guidelines for the evaluation and management of plasma cell dyscrasias, this may directly affect clinical decisions. As new certified methods for serum FLC assays emerge, the need to harmonise patient FLC results becomes increasingly important. In this opinion paper we provide an overview of the current lack of accuracy and harmonisation in serum FLC measurements. The clinical consequence of non-harmonized FLC measurements is that an individual patient may or may not meet certain diagnostic, prognostic, or response criteria, depending on which FLC assay and platform is used. We further discuss whether standardisation of serum FLC measurements is feasible and provide an overview of the steps needed to be taken towards harmonisation of FLC measurements.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据